Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lenalidomide

- PMLiVE

Takeda pipeline hit by fasiglifam failure

Diabetes candidate had been set for a 2015 launch

- PMLiVE

FDA panel backs Takeda’s inflammatory bowel disease drug

Vedolizumab on course for US approval to treat Crohn’s disease and ulcerative colitis

Novartis building

Novartis myeloma drug clears phase III trial

Panobinostat on course to be first in new class of treatment for bone marrow cancer

- PMLiVE

Takeda appoints GSK’s Weber as chief operating officer

Could take on CEO role next year

- PMLiVE

Revlimid performance leads Celgene to trio of PMEAs

Wins Small Company of the Year thanks to work on rare cancer drug

- PMLiVE

Celgene’s Revlimid knocked-back by NICE

Final draft guidance from NICE does not recommend drug for rare bone marrow disorder

- PMLiVE

New US drug discovery institute partners with Takeda

Tri-Institutional Therapeutics Discovery Institute to cover communicable, chronic and rare conditions

- PMLiVE

Takeda appoints new financial head

François-Xavier Roger brings experience from Sanofi and in telecoms

- PMLiVE

FDA grants priority review to Takeda’s colitis drug

Accelerates review time for vedolizumab

- PMLiVE

Takeda continues Actos resurrection as Alzheimer’s drug

Late-stage trial will see if pioglitazone can delay disease progression

Takeda expands Latin American footprint

Opens new subsidiary in Peru

- PMLiVE

Phase III data raise hopes for Takeda’s vedolizumab

Bowel disease drug shows efficacy in ulcerative colitis and Crohn's disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links